Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07629726 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07629726: Recruiting Phase 1 study, sponsored by Kyowa Kirin Co..
NCT07629726 is a Phase 1 study that is actively recruiting participants, run by Kyowa Kirin Co.. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07629726, a Phase 1 study, is actively recruiting participants, sponsored by Kyowa Kirin Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.
Primary Outcome
Number of Subjects Experiencing DLT; DLTs will be evaluated according to NCI-CTCAE Version 6.0.
Interventions
- DRUG KK2430
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT07629726 shows while recruiting
NCT07629726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 1 intervention - of which KK2430 is the first listed.
NCT07629726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07629726 about?
NCT07629726 is a clinical study titled "A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms". KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given ...
What is the current status of trial NCT07629726?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2026-06. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07629726?
The interventions under investigation include: KK2430 (DRUG).
Who is sponsoring clinical trial NCT07629726?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07629726's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia